Altimmune, Inc.
ALT•NASDAQ•Healthcare•Biotechnology

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOJerome Durso
Founded1997
Employees59
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitealtimmune.com
Phone240 654 1450
Address
910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 United States

Corporate Identifiers

CIK0001326190
CUSIP02155H200
ISINUS02155H2004
EIN20-2726770
SIC2834

Leadership Team & Key Executives

Dr. Vipin K. Garg Ph.D.
President, Chief Executive Officer and Director
Dr. M. Scot Roberts Ph.D.
Chief Scientific Officer
Gregory L. Weaver CPA, M.B.A.
Chief Financial Officer
Andrew Shutterly M.S.
Principal Financial and Accounting Officer and Corporate Controller
Bertrand Georges Ph.D.
Chief Technology Officer
Tony Blandin B.S.
Vice President of Quality and Compliance Management
Robin E. Abrams J.D.
General Counsel and Chief Legal Officer
Raymond M. Jordt M.B.A.
Chief Business Officer
Linda M. Richardson
Chief Commercial Officer
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.
Chief Medical Officer